Roche remains on track with sales growth after nine months
Published: Wednesday, Oct 23rd 2024, 07:30
العودة إلى البث المباشر
After the first nine months of 2024, the pharmaceutical company Roche remains on track to achieve its annual targets. The Group also confirmed its guidance for this on Wednesday.
In the first nine months, the Basel-based pharmaceutical group achieved sales of almost 45 billion Swiss francs, an increase of 2 percent. At constant exchange rates, sales rose by 6 percent.
The pharmaceuticals division contributed sales of 34.3 billion Swiss francs, an increase of 3 percent. Roche generated sales of 10.7 billion with its diagnostics, the same amount as in the same period last year. Roche traditionally does not publish profit figures after nine months.
With the reported figures, Roche slightly exceeded analysts' average estimates for Group and pharmaceutical sales.
At the same time, the Group is well on track to achieve its own targets for the year as a whole. At constant exchange rates, the pharmaceutical group continues to expect sales growth in the mid single-digit percentage range. Meanwhile, core earnings per share are expected to increase by a high single-digit percentage. As always, the Group will endeavor to increase the dividend in Swiss francs
©كيستون/إسدا
Arabic 
English 
German 
French 
Spanish